jpnn.com, CHINA - A leading vaccine manufacturer in China, Sinovac Biotech, will conduct research to determine the impact of the Omicron variant on the inactivated Covid-19 vaccine.
"We will also evaluate whether it is necessary to develop a new vaccine to deal with the Omicron variant in the near future," Sinovac said in a statement in Beijing, China, Tuesday.
ALSO SEE: Omicron May Be More Infectious, Says Epidemiologist Dicky Budiman
The Beijing-based vaccine manufacturer has been monitoring the development of cases of the Omicron variant.
"We are also actively collecting information and samples of Omicron variants through our worldwide network of partners," Sinovac said.
ALSO SEE: BioNTech Begins Development of Covid-19 Vaccine Against Omicron
Previously, Sinovac developed an inactivated Covid-19 vaccine for the Gamma and Delta variants.
"If needed, we will immediately develop and launch a new vaccine production on a large scale in order to meet the needs of new vaccinations," said Sinovac. (ant/dil/mcr20/jpnn)
ALSO SEE: Bamsoet Warns Indonesian People of New Variant of Covid-19
This news has been broadcast on JPNN.com with the title: Varian Omicron Mengancam, Sinovac Tidak Tinggal Diam